ECSP16059106A - Composiciones de liberación retardada de linaclotida - Google Patents
Composiciones de liberación retardada de linaclotidaInfo
- Publication number
- ECSP16059106A ECSP16059106A ECIEPI201659106A ECPI201659106A ECSP16059106A EC SP16059106 A ECSP16059106 A EC SP16059106A EC IEPI201659106 A ECIEPI201659106 A EC IEPI201659106A EC PI201659106 A ECPI201659106 A EC PI201659106A EC SP16059106 A ECSP16059106 A EC SP16059106A
- Authority
- EC
- Ecuador
- Prior art keywords
- delayed release
- linachlotide
- release compositions
- compositions
- linaclotide
- Prior art date
Links
- 230000003111 delayed effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 abstract 1
- 229960000812 linaclotide Drugs 0.000 abstract 1
- 108010024409 linaclotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914951P | 2013-12-11 | 2013-12-11 | |
| US201361914952P | 2013-12-11 | 2013-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP16059106A true ECSP16059106A (es) | 2017-02-24 |
Family
ID=52293217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201659106A ECSP16059106A (es) | 2013-12-11 | 2016-07-08 | Composiciones de liberación retardada de linaclotida |
| ECSENADI202172161A ECSP21072161A (es) | 2013-12-11 | 2021-09-28 | Composiciones de liberación retardada de linaclotida |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202172161A ECSP21072161A (es) | 2013-12-11 | 2021-09-28 | Composiciones de liberación retardada de linaclotida |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US20160310560A1 (enExample) |
| EP (2) | EP3079669B1 (enExample) |
| JP (4) | JP6964380B2 (enExample) |
| KR (3) | KR102509291B1 (enExample) |
| CN (3) | CN112569199A (enExample) |
| AU (3) | AU2014362220B2 (enExample) |
| CA (1) | CA2933587C (enExample) |
| CL (1) | CL2016001424A1 (enExample) |
| CY (1) | CY1123953T1 (enExample) |
| DK (1) | DK3079669T3 (enExample) |
| EA (1) | EA201691216A1 (enExample) |
| EC (2) | ECSP16059106A (enExample) |
| ES (1) | ES2838007T3 (enExample) |
| HR (1) | HRP20201753T1 (enExample) |
| HU (1) | HUE052981T2 (enExample) |
| IL (2) | IL246155A0 (enExample) |
| LT (1) | LT3079669T (enExample) |
| MX (2) | MX386584B (enExample) |
| NZ (2) | NZ759512A (enExample) |
| PE (2) | PE20211976A1 (enExample) |
| PH (1) | PH12016501122B1 (enExample) |
| PL (1) | PL3079669T3 (enExample) |
| PT (1) | PT3079669T (enExample) |
| RS (1) | RS61133B1 (enExample) |
| SG (2) | SG11201604729QA (enExample) |
| SI (1) | SI3079669T1 (enExample) |
| SM (1) | SMT202000686T1 (enExample) |
| UA (1) | UA119335C2 (enExample) |
| WO (2) | WO2015089326A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| WO2016020901A1 (en) | 2014-08-07 | 2016-02-11 | Acerta Pharma B.V. | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate |
| CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2016125064A1 (en) * | 2015-02-02 | 2016-08-11 | Aurobindo Pharma Ltd | Stable compositions comprising linaclotide |
| JP2018516937A (ja) * | 2015-06-05 | 2018-06-28 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | リナクロチドの改変または標的放出製剤 |
| US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2017156214A1 (en) * | 2016-03-11 | 2017-09-14 | Gateway Pharmaceutical LLC | Pharmaceutical compositions for colon-specific delivery |
| US11534404B2 (en) * | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| CN110475564A (zh) * | 2016-12-21 | 2019-11-19 | 硬木药品公司 | 用利那洛肽的修饰的或延迟释放制剂治疗肠易激综合征的方法 |
| KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
| EA202092275A1 (ru) * | 2018-03-23 | 2021-02-09 | Палатин Текнолоджиз, Инк. | Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN114206324A (zh) * | 2019-06-10 | 2022-03-18 | 硬木药品公司 | 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛 |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| CN110935007B (zh) * | 2019-12-12 | 2023-06-23 | 烟台大学 | 利那洛肽复方组合物、制剂及其用途和制备方法 |
| GB202017863D0 (en) * | 2020-11-12 | 2020-12-30 | Intract Pharma Ltd | Novel compositions |
| CN115105582A (zh) * | 2021-03-17 | 2022-09-27 | 江苏豪森药业集团有限公司 | 一种含利那洛肽或其盐的药物组合物及其制备方法 |
| WO2022245650A1 (en) * | 2021-05-19 | 2022-11-24 | Alberto Paz | Orally administered compositions for cancer treatment |
| IL319961A (en) * | 2022-10-03 | 2025-05-01 | Brim Biotechnology Inc | Preparations including PEDF-derived short peptides (PDSP) and their uses |
| TW202440065A (zh) * | 2022-12-28 | 2024-10-16 | 日商中外製藥股份有限公司 | 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN201252259Y (zh) * | 2008-07-24 | 2009-06-03 | 富士康(昆山)电脑接插件有限公司 | 电连接器 |
| RS60101B1 (sr) * | 2008-08-15 | 2020-05-29 | Ironwood Pharmaceuticals Inc | Formulacije koje sadrže linaklotid za oralnu primenu |
| JP5964589B2 (ja) * | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法 |
| US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
| WO2011019819A1 (en) * | 2009-08-12 | 2011-02-17 | Forest Laboratories Holdings Limited | Orally disintegrating compositions of linaclotide |
| US8748573B2 (en) * | 2009-08-06 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | Formulations comprising linaclotide |
| RU2012109415A (ru) * | 2009-08-13 | 2013-09-20 | Айронвуд Фармасьютикалз, Инк. | Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы |
| CA2790213A1 (en) * | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| ES2763404T3 (es) * | 2010-08-11 | 2020-05-28 | Ironwood Pharmaceuticals Inc | Formulaciones estables de linaclotida |
| US20140162963A1 (en) * | 2010-09-11 | 2014-06-12 | Forest Laboratories Holdings Limited | Treatment of Constipation-Predominant Irritable Bowel Syndrome |
| JP2012155108A (ja) * | 2011-01-26 | 2012-08-16 | Kyocera Document Solutions Inc | 現像ローラ、現像装置および画像形成装置 |
| CN104053449B (zh) * | 2011-08-17 | 2016-12-07 | 硬木药品公司 | 胃肠疾患的治疗 |
| WO2013047795A1 (ja) * | 2011-09-30 | 2013-04-04 | アステラス製薬株式会社 | 粒子状医薬組成物 |
| JP2016521249A (ja) * | 2012-07-12 | 2016-07-21 | フォレスト ラボラトリーズ ホールディングス リミテッド | リナクロチド組成物 |
| EP2958577A2 (en) * | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
-
2014
- 2014-11-12 UA UAA201607434A patent/UA119335C2/uk unknown
- 2014-12-11 PE PE2021000748A patent/PE20211976A1/es unknown
- 2014-12-11 NZ NZ759512A patent/NZ759512A/en unknown
- 2014-12-11 EP EP14824655.6A patent/EP3079669B1/en active Active
- 2014-12-11 WO PCT/US2014/069838 patent/WO2015089326A1/en not_active Ceased
- 2014-12-11 SM SM20200686T patent/SMT202000686T1/it unknown
- 2014-12-11 PH PH1/2016/501122A patent/PH12016501122B1/en unknown
- 2014-12-11 KR KR1020217039962A patent/KR102509291B1/ko active Active
- 2014-12-11 PT PT148246556T patent/PT3079669T/pt unknown
- 2014-12-11 KR KR1020237008167A patent/KR20230039764A/ko not_active Ceased
- 2014-12-11 CN CN202011156517.1A patent/CN112569199A/zh active Pending
- 2014-12-11 DK DK14824655.6T patent/DK3079669T3/da active
- 2014-12-11 RS RS20201435A patent/RS61133B1/sr unknown
- 2014-12-11 HR HRP20201753TT patent/HRP20201753T1/hr unknown
- 2014-12-11 NZ NZ721952A patent/NZ721952A/en unknown
- 2014-12-11 CN CN202210517834.4A patent/CN115089556A/zh active Pending
- 2014-12-11 CN CN201480075352.1A patent/CN106659687A/zh active Pending
- 2014-12-11 US US15/103,634 patent/US20160310560A1/en not_active Abandoned
- 2014-12-11 SG SG11201604729QA patent/SG11201604729QA/en unknown
- 2014-12-11 KR KR1020167018606A patent/KR102337809B1/ko active Active
- 2014-12-11 SI SI201431715T patent/SI3079669T1/sl unknown
- 2014-12-11 EA EA201691216A patent/EA201691216A1/ru unknown
- 2014-12-11 CA CA2933587A patent/CA2933587C/en active Active
- 2014-12-11 AU AU2014362220A patent/AU2014362220B2/en not_active Ceased
- 2014-12-11 ES ES14824655T patent/ES2838007T3/es active Active
- 2014-12-11 WO PCT/US2014/069851 patent/WO2015089335A1/en not_active Ceased
- 2014-12-11 US US15/103,616 patent/US20160310559A1/en not_active Abandoned
- 2014-12-11 EP EP20198666.8A patent/EP3821881A1/en active Pending
- 2014-12-11 PE PE2016000804A patent/PE20161373A1/es unknown
- 2014-12-11 PL PL14824655T patent/PL3079669T3/pl unknown
- 2014-12-11 HU HUE14824655A patent/HUE052981T2/hu unknown
- 2014-12-11 JP JP2016538745A patent/JP6964380B2/ja not_active Expired - Fee Related
- 2014-12-11 LT LTEP14824655.6T patent/LT3079669T/lt unknown
- 2014-12-11 SG SG10201804817TA patent/SG10201804817TA/en unknown
- 2014-12-11 MX MX2016007625A patent/MX386584B/es unknown
-
2016
- 2016-06-09 IL IL246155A patent/IL246155A0/en unknown
- 2016-06-10 MX MX2021011906A patent/MX2021011906A/es unknown
- 2016-06-10 CL CL2016001424A patent/CL2016001424A1/es unknown
- 2016-07-08 EC ECIEPI201659106A patent/ECSP16059106A/es unknown
-
2017
- 2017-02-17 US US15/435,701 patent/US20170157200A1/en not_active Abandoned
- 2017-09-28 US US15/718,075 patent/US20180015139A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029432A patent/JP2019073559A/ja active Pending
- 2019-09-11 US US16/567,082 patent/US20200038476A1/en not_active Abandoned
-
2020
- 2020-04-01 AU AU2020202319A patent/AU2020202319B2/en not_active Ceased
- 2020-11-26 CY CY20201101128T patent/CY1123953T1/el unknown
-
2021
- 2021-05-06 JP JP2021078445A patent/JP7483656B2/ja active Active
- 2021-05-06 IL IL283012A patent/IL283012A/en unknown
- 2021-09-28 EC ECSENADI202172161A patent/ECSP21072161A/es unknown
- 2021-10-18 US US17/503,601 patent/US20220031802A1/en not_active Abandoned
-
2022
- 2022-03-18 AU AU2022201891A patent/AU2022201891A1/en not_active Abandoned
-
2023
- 2023-07-14 JP JP2023115832A patent/JP2023126475A/ja active Pending
- 2023-11-09 US US18/505,414 patent/US20240075094A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21072161A (es) | Composiciones de liberación retardada de linaclotida | |
| CL2015002335A1 (es) | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas. | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| BR112016000489A2 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
| UY34651A (es) | ?formas de dosificación de liberación inmediata resistentes a la manipulación, procesos para prepararlas, métodos y usos de las mismas?.. | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
| UY35661A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que lo s contienen | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| CL2015000408A1 (es) | Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. | |
| BR112015031979A2 (pt) | letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir. | |
| ECSP16074478A (es) | Compuestos novedosos | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CR20120549A (es) | Composiciones farmacèuticas que comprenden hidromorfona y naloxona | |
| SV2017005412A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| CL2015002488A1 (es) | Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| MX2016003215A (es) | Preparacion y uso de una composicion para la prevencion y mitigacion de los efectos de la radiacion. | |
| UY34552A (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen |